Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Hutchmed China Ltd ADR (NQ: HCM ) 18.63 +0.63 (+3.50%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Hutchmed China Ltd ADR < Previous 1 2 3 4 5 6 7 8 Next > 12 Health Care Stocks Moving In Monday's Pre-Market Session May 02, 2022 Via Benzinga The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More April 24, 2022 Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... Via Benzinga Week In Review: Wuhan Binhui Raises $47 Million For Oncolytic Virus Products April 23, 2022 Wuhan Binhui Biotech closed a $47 million Series B financing to support its R&D of oncolytic virus products. Trevena, a Philadelphia-area CNS biopharma, closed a $40 million revenue-based financing... Via Talk Markets Stocks That Hit 52-Week Highs On Thursday July 29, 2021 Thursday's morning session saw 167 companies set new 52-week highs. Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new... Via Benzinga The Gift Chinese Regulators Just Gave Tech Stocks Like Alibaba And BeiGene April 04, 2022 Auditing issues persist for some 270 companies trading in the U.S. But they could ease. Via Investor's Business Daily Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates April 01, 2022 Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... Via Benzinga Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework April 01, 2022 Via Benzinga Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs March 28, 2022 As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China. Via InvestorPlace Which Chinese Stocks Could Get Delisted? 6 Companies to Watch. March 25, 2022 Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way. Via InvestorPlace The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings March 13, 2022 Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... Via Benzinga Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today? March 11, 2022 Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next. Via InvestorPlace What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today March 11, 2022 Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM... Via Benzinga Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat March 11, 2022 Key Takeaways U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO... Via Benzinga Chinese Stocks Are Falling: What's Going On? March 10, 2022 Shares of multiple Chinese companies are trading lower Thursday following reports the U.S. Securities and Exchange Commision has identified multiple US-listed ADRs as... Via Benzinga Why BeiGene — And 2 Other China-Based Biotechs — Are In Trouble March 10, 2022 The SEC is calling out a several stocks for non-compliance. Could they face delisting? Via Investor's Business Daily Hutchmed Clocks Over 50% Jump In FY21 Sales Boosted By Three Oncology Drugs, Announces CEO Transition March 03, 2022 Hutchmed (China) Limited (NASDAQ: HCM) reported FY21 sales of $356.1 million, up 56% Y/Y, driven by commercial progress on three in-house developed oncology drugs... Via Benzinga Earnings Scheduled For March 3, 2022 March 03, 2022 Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... Via Benzinga Week In Review: Biopharma Deals Slow During Chinese New Year Week February 05, 2022 Amid a slow week, Shanghai's HanBio Therapeutics raised $40 million in a Series A financing to advance its innovative biologic products. HanBio is an early R&D company that was incubated by Sunshine... Via Talk Markets 58 Biggest Movers From Yesterday December 17, 2021 Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price... Via Benzinga 31 Stocks Moving In Thursday's Mid-Day Session December 16, 2021 Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce... Via Benzinga 18 Stocks Moving in Thursday's Pre-Market Session December 16, 2021 Gainers Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO... Via Benzinga 61 Biggest Movers From Yesterday November 23, 2021 Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare... Via Benzinga Exposures Product Safety 40 Stocks Moving In Monday's Mid-Day Session November 22, 2021 Gainers iSpecimen Inc. (NASDAQ: ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to support new advanced research on COVID-19 seeking... Via Benzinga Exposures COVID-19 20 Stocks Moving in Monday's Pre-Market Session November 22, 2021 Gainers Astra Space, Inc. (NASDAQ: ASTR) rose 39.6% to $13.30 in pre-market trading after declining around 3% on Friday. Astra Space recently reported a Q3 loss of $0.06 per... Via Benzinga Week In Review: Broncus Stages $200 Million Hong Kong IPO For Pulmonary Devices September 25, 2021 Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. The IPO was priced at the top end of... Via Talk Markets Topics Initial Public Offering Exposures Securities Market HUTCHMED's Lymphoma Candidate Secures Breakthrough Tag In China September 13, 2021 The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation to HUTCHMED (China) Limited... Via Benzinga The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod September 08, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... Via Benzinga Exposures Product Safety Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal August 14, 2021 Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... Via Talk Markets Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China August 09, 2021 Epizyme Inc (NASDAQ: EPZM) and HUTCHMED (China) Limited (NASDAQ: HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (... Via Benzinga Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China August 08, 2021 From Epizyme, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
